Skip to content
Get alerts
GovInfoNow
Stop using now Drug recall · FDA · Published October 2, 2023

Pfizer 2% Lidocaine Injection Recall: Glass Particulate Matter Hazard

Pfizer recalls 2% Lidocaine HCl Injection (100mg/5mL) with glass particulate matter. This could cause injury if injected. Affected units have specific NDC and lot numbers.

Plain-English summary generated from official FDA data by GovInfoNow · Published by Carlos Caban · How we make summaries

🇺🇸 FDA recall #D-0102-2024DrugPfizer ›
Take action

Contact the company

Recalling firmPfizer Inc.235 East 42nd Street · New York, NY 10017-5703
✎ GovInfoNow plain-language explainer

Pfizer is recalling 2% Lidocaine HCl Injection (100mg/5mL) due to glass particles in the syringe. This could cause injury if injected, so affected users should stop using the product. Read more at govinfonow.com/recall/33074-pfizer-2-lidocaine-injection-recall-glass-particulate-matter-hazard.

Source Summary by GovInfoNow · govinfonow.com/recall/33074-pfizer-2-lidocaine-injection-recall-glass-particulate-matter-hazard · Updated August 18, 2026 · FDA enforcement record: FDA #D-0102-2024

Cite this page

“Pfizer 2% Lidocaine Injection Recall: Glass Particulate Matter Hazard.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/33074-pfizer-2-lidocaine-injection-recall-glass-particulate-matter-hazard. Based on FDA recall #D-0102-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0102-2024%22&limit=1).

The FDA announced on Oct. 2, 2023, that Pfizer Inc. voluntarily recalled 3,200 vials of 2% Lidocaine HCl Injection due to the presence of glass particulate matter. The recall was classified as Class I and has since been terminated.

How to tell if you have it

  • Brand: Pfizer
  • Product: 2% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT Unit of Use Syringe
  • NDC: 0409-4903-11
  • Lot: GH6567
  • Expiration: 7/1/2024

The hazard

The recall addresses the presence of particulate matter identified as glass within the injection vials. The FDA classified this hazard as Class I, indicating a situation where use could cause serious adverse health consequences or death.

Context

GovInfoNow's records show Pfizer Inc. has issued 71 other recalls since Nov. 26, 2012. Recent Pfizer recalls include a Sodium Bicarbonate Injection recall on Aug. 4, 2025, due to lack of sterility assurance, and a Bicillin L-A injectable recall on July 10, 2025, for particulate risk. Other recent recalls of similar products include Sun Pharmaceutical's DOXOrubin Liposome Injection recall (May 12, 2026) and American Regent's Papaverine HCl Injection recall (July 24, 2026).

How to tell if you have this one

Check for the NDC code 0409-4903-11 and lot number GH6567 on the syringe packaging. The product is a 2% Lidocaine HCl Injection (100mg/5mL) with a glass syringe.

  • Brand
    Pfizer
  • Category
    Drug
FDA recall event · 3 products

All 3 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class I
  • Status
    Terminated
  • Distribution
    Nationwide in the US and Puerto Rico. The products were not distributed to government accounts or foreign consignees.
Recall numberProduct, codes & lotsQuantityNDC
D-0100-20244.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5mEq/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Hospira Inc., Lake Forest, IL 60045, NDC 0409-5534-24; Lot#: GJ5007, Exp. 8/1/202424,900 vials—
D-0101-20241% Lidocaine HCl Injection, USP, 50mg/5mL(10mg/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Distributed by Hospira Inc., Lake Forest, IL 60045, NDC 0409-4904-11; Lot#: 42290DK, Exp. 6/1/202421,390 vials0409-4903-11, 0409-4903-34, 0409-4904-11, 0409-4904-34, 0409-1323-15, 0409-1323-05, 0409-9137-11, 0409-9137-05
D-0102-20242% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Distributed by Hospira Inc., Lake Forest, IL 60045, NDC 0409-4903-11; Lot#: GH6567, Exp. 7/1/20243,200 vials0409-4903-11, 0409-4903-34, 0409-4904-11, 0409-4904-34, 0409-1323-15, 0409-1323-05, 0409-9137-11, 0409-9137-05
Based on the official FDA remedy

What to do — step by step

  1. Stop Using It Now

    Immediately stop using the recalled 2% Lidocaine HCl Injection (100mg/5mL) syringes with NDC 0409-4903-11 and lot number GH6567.

Where it went and when

Where it was distributed

Distributed nationwide, and outside the U.S.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide in the US and Puerto Rico. The products were not distributed to government accounts or foreign consignees.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide, and outside the U.S.

Recall timeline

FDA terminated this recall 16 months after the firm started it.

1. Firm started the recall: Oct 2, 202312. FDA classified it Class I: Nov 9, 202323. Published in FDA’s Enforcement Report: Nov 15, 202334. FDA terminated the recall: Feb 14, 2025420232025
  1. Firm started the recall
  2. FDA classified it Class I
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

American Health Packaging Recalls Metoclopramide Tablets Due to Foreign Drug Presence
American Health PackagingTeva Recalls Metoclopramide Tablets Due to Foreign Contaminants
Teva Pharmaceuticals USA, IncPreferred Pharma Recalls Lidocaine Ointment Due to Content Issues
Preferred Pharmaceuticals, Inc.Northstar Rx Recalls Tretinoin Cream Due to Impurities
SUN PHARMACEUTICAL INDUSTRIES INCApothecary Pharma Recalls Tirzepatide Injections Due to Sterility Risk
Apothecary Pharma LLC

Latest drug recalls

Apotex Corp. recalls Paroxetine Extended-Release Tablets, 37.5mg, 30-count bottle, Rx only, Manufactured by: Apotex Inc., Toronto, Ontario,
Apotex · September 23, 2026Cipla USA, Inc. recalls Fosfomycin Tromethamine Granules for Oral Solution, (Equivalent to 3 Grams of Fosfomycin), 1 Single-Dose Sachet, Rx
Cipla USA · September 18, 2026Ajanta Pharma USA Inc recalls Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only, Marketed by: Ajanta Pharma USA Inc.,
Ajanta Pharma · September 17, 2026Insight Pharmaceuticals LLC, a Prestige Consumer Healthcare company recalls Clear Eyes Redness Relief, Lubricant/Redness Reliever Eye Drops (glycerin 0.25%, naphazoline hydrochloride 0.012%) with
Insight Pharmaceuticals · September 15, 2026K.C. Pharmaceuticals, Inc. recalls Sterile Lubricant Dry Eye Relief Eye Drops, 0.5 FL OZ (15 mL); a) LEADER, DISTRIBUTED BY CARDINAL HEALTH, DUBLIN, OHIO
Leader / TopCare / Crocodile Tears · September 11, 2026Amneal Pharmaceuticals, LLC recalls Estradiol Gel, 0.1%, 0.25 mg, 30-packets per carton, Rx only, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater,
Amneal Pharmaceuticals · September 8, 2026

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0102-2024 (October 2, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0102-2024 to see it in context.
  • Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA